局部晚期乳腺癌新辅助化疗

doi:10.3760/cma.j.issn.1673-422X.2015.12.009

摘要/Abstract

摘要： 新辅助化疗是局部晚期乳腺癌综合治疗的常用手段之一，以蒽环类和紫杉烷类为主要化疗药物。近年来，分子靶向药物在显著提高化疗疗效的同时，也为临床提供了更多选择和治疗思路。目前研究较为广泛的靶向治疗药物包括曲妥珠单抗、拉帕替尼、帕妥珠单抗、TDM1和贝伐珠单抗。

关键词: 乳腺肿瘤, 新辅助化疗

Abstract: Neoadjuvant chemotherapy is one of the common means in multidisciplinary treatment of locally advanced breast cancer, with anthracyclines and taxanes as main chemotherapeutic drugs. In recent years, molecular target agents have significantly improved the efficacy of chemotherapy, as well as have provided more choices and ideas for clinical treatment. Currently, the widely studied molecular targeted drugs include trastuzumab, lapatinib, pertuzumab, TDM1 and bevacizumab.

Key words: Breast neoplasms, Neoadjuvant chemotherapy

刘慧,芮景. 局部晚期乳腺癌新辅助化疗[J]. 国际肿瘤学杂志, 2015, 42(12): 916-919.

Liu Hui, Rui Jing. Neoadjuvant chemotherapy for locally advanced cancer[J]. Journal of International Oncology, 2015, 42(12): 916-919.

参考文献

［1］ Zardavas D, Piccart M. Neoadjuvant therapy for breast cancer［J］. Annu Rev Med, 2015, 66: 31-48. ［2］ Zaharia M, Gómez H. Neoadjuvant chemotherapy in the treatment of locally advanced breast cancer［J］. Rev Peru Med Exp Salud Publica, 2013, 30(1): 73-78. ［3］ Cardoso F, Costa A, Norton L, et al. ESOESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)［J］. Ann Oncol, 2014, 23(5): 489-502. ［4］ Guha M. PARP inhibitors stumble in breast cancer［J］. Nat Biotechnol, 2011, 29(5): 373-374. ［5］ Silver D, Richardson A, Eklund A, et al. Efficacy of neoadjuvant cisplatin in triplenegative breast cancer［J］. J Clin Oncol, 2010, 28(7): 1145-1153. ［6］ Sikov WM, Berry DA, Perou CM, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant onceperweek paclitaxel followed by dosedense doxorubicin and cyclophosphamide on pathologic complete response rates in stage Ⅱ to Ⅲ triplenegative breast cancer: CALGB 40603 (Alliance)［J］. J Clin Oncol, 2015, 33(1): 13-21. ［7］ Pierga JY, Delaloge S, Espié M, et al. A multicenter randomized phase Ⅱ study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients［J］. Breast Cancer Res Treat, 2010, 122(2): 429-473. ［8］ Earl HM, Vallier AL, Hiller L, et al. Effects of the addition of gemcitabine, and paclitaxelfirst sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with highrisk early breast cancer (NeotAnGo): an openlabel, 2×2 factorial randomised phase 3 trial［J］. Lancet Oncol, 2014, 15(2): 201-212. ［9］ Vriens BE, Aarts MJ, de Vries B, et al. Doxorubicin/cyclophosphamide with concurrent versus sequential docetaxel as neoadjuvant treatment in patients with breast cancer［J］. Eur J Cancer, 2013, 49 (15): 3102-3110. ［10］ Eiermann W, Pienkowski T, Crown J, et al. Phase Ⅲ study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2normal, nodepositive breast cancer: BCIRG005 trial［J］. J Clin Oncol, 2011, 29(29): 3877-3884. ［11］ Untch M, Fasching PA, Konecny GE, et al. PREPARE trial: a randomized phase Ⅲ trial comparing preoperative, dosedense, doseintensified chemotherapy with epirubicin, paclitaxel and CMF versus a standarddosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer—results at the time of surgery［J］. Ann Oncol, 2011, 22(9): 1988-1998. ［12］ von Minckwitz G, Blohmer JU, Costa SD, et al. Responseguided neoadjuvant chemotherapy for breast cancer［J］. J Clin Oncol, 2013, 31(29): 3623-3630. ［13］ Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2negative cohort［J］. Lancet, 2010, 375(9712): 377-384. ［14］ Untch M, Rezai M, Loibl S, et al. Neoadjuvant treatment with trastuzumab in HER2positive breast cancer: results from the GeparQuattro study［J］. J Clin Oncol, 2010, 28(12): 2024-2031. ［15］ Baselga J, Bradbury I, Eidtmann H, et al. Lapatinib with trastuzumab for HER2positive early breast cancer (NeoALTTO): a randomised, openlabel, multicentre, phase 3 trial［J］. Lancet, 2012, 379(9816): 633-640. ［16］ Robidoux A, Tang G, Rastogi P, et al. Lapatinib as a component of neoadjuvant therapy for HER2positive operable breast cancer (NSABP protocol B41): an openlabel, randomised phase 3 trial［J］. Lancet Oncol, 2013, 14(12): 1183-1192. ［17］ Rimawi MF, Mayer IA, Forero A, et al. Multicenter phase Ⅱ study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2overexpressing breast cancer: TBCRC 006［J］. J Clin Oncol, 2013, 31(14): 1726-1731. ［18］ Swain SM, Kim SB, Cortés J, et al. Pertuzumab, trastuzumab, and docetaxel for HER2positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, doubleblind, placebocontrolled, phase 3 study［J］. Lancet Oncol, 2013, 14(6): 461-471. ［19］ Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2positive breast cancer (NeoSphere): a randomised multicentre, openlabel, phase 2 trial［J］. Lancet Oncol, 2012, 13(1): 25-32. ［20］ Schneeweiss A, Chia S, Hickish T, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracyclinecontaining and anthracyclinefree chemotherapy regimens in patients with HER2positive early breast cancer: a randomized phase Ⅱ cardiac safety study (TRYPHAENA)［J］. Ann Oncol , 2013, 24(9): 2278-2284. ［21］ Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2positive advanced breast cancer［J］. N Engl J Med, 2012, 367(19): 1783-1791. ［22］ Pierga JY, Petit T, Delozier T, et al. Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2positive breast cancer (BEVERLY2): an openlabel, singlearm phase 2 study［J］. Lancet Oncol, 2012, 13(4): 375-384. ［23］ Coudert B, Pierga JY, MouretReynier MA, et al. Use of ［(18)F］FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in ［(18)F］FDG PETpredicted nonresponders (AVATAXHER): an openlabel, randomised phase 2 trial［J］. Lancet Oncol, 2014, 5(13): 1493-1502. ［24］ Iqbal J, Bano K, Saeed A, et al. Survival of women with locally advanced breast cancer at a teaching hospital in Lahore［J］. J Pak Med Assoc, 2010, 60(9): 721-725. ［25］ von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes［J］. J Clin Oncol, 2012, 30(15): 1796-1804. ［26］ de Azambuja E, Holmes A, PiccartGebhart M, et al. Lapatinib with trastuzumab for HER2positive early breast cancer (NeoALTTO): survival outcomes of a randomised, openlabel, multicentre, phase 3 trial and their association with pathological complete response［J］. Lancet Oncol, 2014, 15(10): 1137-1146.

[1]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[2]	萨蔷, 徐航程, 王佳玉. 乳腺癌免疫治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 227-234.
[3]	杨智, 陆以乔, 顾花艳, 丁佳玲, 郭贵龙. 肿瘤微环境介导乳腺癌靶向治疗耐药的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 235-238.
[4]	陈波光, 王苏贵, 张永杰. 血清胆碱酯酶与炎症标志物在ⅠA~ⅢA期乳腺癌预后中的作用[J]. 国际肿瘤学杂志, 2024, 51(2): 73-82.
[5]	顾花艳, 朱腾, 郭贵龙. 乳房微生物群与乳腺癌：现状与未来[J]. 国际肿瘤学杂志, 2024, 51(1): 55-58.
[6]	王景, 许文婷. 中性粒细胞与淋巴细胞比值、癌胚抗原联合凝血指标对直径≤1.0 cm的良恶性乳腺结节鉴别诊断价值研究[J]. 国际肿瘤学杂志, 2023, 50(9): 520-526.
[7]	冯诚天, 黄芙蓉, 曹世玉, 王健宇, 南丁阿比雅思, 姜永冬, 朱娟英. HER2阳性乳腺癌患者HER2表达水平与影像学特征的关系[J]. 国际肿瘤学杂志, 2023, 50(9): 527-531.
[8]	冯东旭, 吴炜, 高平发, 王军, 施丽娟, 陈大伟, 李文兵, 张美峰. miR-451通过调控Rho/ROCK1信号通路对乳腺癌细胞糖酵解及凋亡的影响[J]. 国际肿瘤学杂志, 2023, 50(8): 449-456.
[9]	王文德, 曾德. 乳腺癌内分泌治疗耐药的机制研究进展[J]. 国际肿瘤学杂志, 2023, 50(6): 352-356.
[10]	李青珊, 谢鑫, 张楠, 刘帅. 放疗联合系统治疗在乳腺癌中的应用进展[J]. 国际肿瘤学杂志, 2023, 50(6): 362-367.
[11]	朱军, 黄美金, 李媛, 刘泽刚, 荀欣, 陈宏. HER2低表达乳腺癌的靶向治疗研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 236-240.
[12]	周婷, 徐少华, 梅林. 贝伐珠单抗联合卡培他滨治疗晚期乳腺癌的有效性及安全性[J]. 国际肿瘤学杂志, 2023, 50(3): 144-149.
[13]	范珊琳, 汪品秀, 孔飞, 周玉洁, 袁文臻. 胃癌新辅助化疗后肿瘤退缩分级预测因素的研究进展[J]. 国际肿瘤学杂志, 2023, 50(2): 112-116.
[14]	黎立喜, 张娣, 罗扬, 马飞. PARP抑制剂在乳腺癌中的临床应用[J]. 国际肿瘤学杂志, 2023, 50(2): 91-96.
[15]	陈群响, 张晓钰, 张妍, 张凯翔, 李捷, 陈曦. 伊尼妥单抗联合长春瑞滨治疗HER2阳性转移性乳腺癌1例[J]. 国际肿瘤学杂志, 2023, 50(12): 763-765.